IMMURON LTD-SPON ADR (IMRN)

US45254U1016 - ADR

1.91  +0.01 (+0.53%)

IMMURON LTD-SPON ADR

NASDAQ:IMRN (12/30/2024, 12:18:06 PM)

1.91

+0.01 (+0.53%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-168.77%
Sales Q2Q%108.61%
CRS20.17
6 Month-21.49%
Overview
Earnings (Last)08-28 2024-08-28
Earnings (Next)N/A N/A
Ins Owners7.77%
Inst OwnersN/A
Market Cap10.89M
Shares5.70M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts0
Short Float %0%
Short Ratio0.85
IPO04-30 1999-04-30
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IMRN Daily chart

Company Profile

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company is headquartered in Melbourne, Victoria. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Company Info

IMMURON LTD-SPON ADR

L 3 62 Lygon St

Melbourne VICTORIA 3053

P: 61398245254

CEO: Jerry Kanellos

Employees: 7

Website: https://www.immuron.com.au

IMRN News

News Image24 days ago - Virtual Investor ConferencesUPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

News Image24 days ago - Virtual Investor ConferencesSmall Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

News Imagea month ago - ACCESSWIREWinter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
News Imagea month ago - Virtual Investor ConferencesSmall Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

News Imagea month ago - Immuron LimitedImmuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
News Imagea month ago - Immuron LimitedImmuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...

IMRN Twits

Here you can normally see the latest stock twits on IMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example